Brain Ischemia Market Research Report - Global Forecast till 2030

Brain Ischemia Market Research Report: Information by Condition Type (Focal Brain Ischemia and Global Brain Ischemia), Treatment [Angioplasty, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and others], End User (Hospitals & Clinics, Research & Academic Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2030

ID: MRFR/MED/0915-HCR | December 2022 | Region: Global | 85 Pages         

Brain Ischemia Market

The Brain ischemia market is projected to reach USD 1,473.7 Million by 2030 at 7.6% CAGR during the forecast period 2022-2030.

Segmentation

By Condition Type Focal Brain Ischemia and Global Brain Ischemia
Treatment Angioplasty Beta Blockers Angiotensin-Converting Enzyme Inhibitors and others
End User Hospitals & Clinics Research & Academic Institutes and others

Key Players

  • Taxus Cardium (US)
  • Edwards Lifesciences Corporation (US)
  • Boston Scientific Corporation (US)
  • Merck KGaA (Germany)
  • Medtronic (Ireland)
  • Cook Medical (US)
  • Novartis AG (Switzerland)
  • Boehringer Ingelheim International GmbH (Germany)
  • Abbott (US)
  • Becton
  • Dickinson and Company (US)
  • Johnson & Johnson Services Inc. (US)
  • Bayer AG (Germany)
  • and AstraZeneca (UK)

Drivers

  • Increasing burden of ischemic strokes and growth in the geriatric population.
Speak to Analyst Request a Free Sample

Brain Ischemia Market Overview

The Brain ischemia market is projected to reach USD 1,473.7 Million  by 2030 at 7.6% CAGR during the forecast period 2022-2030.

When blood flow to the brain is insufficient to fulfill metabolic demands, brain ischemia ensues. This disorder causes cerebral hypoxia, or a lack of oxygen in the brain, which results in brain tissue death, cerebral infarction, or ischemic stroke. Along with subarachnoid hemorrhage and intracerebral hemorrhage, this is a kind of stroke. Ischemia is divided into two types: localized ischemia and global ischemia. There are several risk factors for brain ischemia, and other illness consequences may also contribute to the ischemic state. In the United States, around 795,000 people experience a stroke each year, with approximately 610,000 of these being new stroke cases.

Vision, body movement, and speech problems are the most common signs of brain ischemia. Brain ischemia can be caused by a variety of factors, including sickle cell anemia and congenital heart abnormalities. Unconsciousness, blindness, coordination issues, and physical weakness are all symptoms of brain ischemia. Stroke, cardiorespiratory arrest, and irreversible brain injury are all possible outcomes of brain ischemia. It has been linked to some disorders and abnormalities. In comparison to their healthy counterparts, those with sickle cell anemia, constricted blood vessels, ventricular tachycardia, plaque buildup in the arteries, blood clots, severely low blood pressure as a result of a heart attack, and congenital heart defects are more prone to brain ischemia.

COVID-19 Analysis

More than 239.1 million confirmed cases had been recorded worldwide during 2021. SARS-COV-2 (the virus that causes COVID-19) mostly affects the respiratory system; COVID-19 has caused very few neurological problems. The need for the brain ischemia market and patient engagement solutions has risen dramatically in response to the outbreak's urgency. To provide optimal treatment, most hospitals and healthcare facilities are actively attempting to spread patient monitoring to home care settings or other temporary setups. In contrast to Brain ischemia market Growth, COVID-19 has resulted in a considerable increase in demand for ventilators, and manufacturers are currently focusing their efforts on meeting the growing demand for ventilators, including other breathing equipment. The pandemic is expected to harm the market, owing to hospitals' increased attention on creating COVID-19-specific ICUs and the temporary suspension of production and manufacturing locations.

Brain Ischemia Market Dynamics

Drivers

The rising prevalence of ischemic strokes and the aging population, both of which are susceptible to brain ischemia, as well as the rising number of patients suffering from diabetes, obesity, hypertension, and other related diseases, are expected to propel the Brain ischemia market growth during the forecast period. The market Outlook is predicted to expand due to factors such as the rising prevalence of ischemic strokes and the rise in the geriatric population, which is prone to brain ischemia. Ischemic stroke is the third leading cause of death among adults. Furthermore, firms' increased focus on developing medications to treat brain ischemia is projected to promote Brain ischemia market trends.

Restraints

The rigid administration restrictions and limited accessibility of treatment alternatives, as well as treatment costs, are expected to stymie the Brain ischemia market Share shortly. The high market Value and technologies is a major restraint on the global market, particularly in poorer countries with weak reimbursement systems.

The brain ischemia market report also includes the detailed analysis for each country, including growth in healthcare capital expenditure, installed base of various types of products for the market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios, as well as their impact on the market Outlook.

Study Objectives

The report focuses on research and analyses of the global Brain ischemia market size (value and volume) by company, major regions/countries, types, and applications, and historical data with a forecast.

The report analyses the competitive developments in the market, such as market expansions, partnerships, new product launches, and acquisitions, and also develops a strategic profile of the key players and a thorough analysis of their growth strategies.

The report includes the identification of the various subsegments of the market to better comprehend its structure and to disseminate precise information on the major aspects impacting market growth (growth potential, drivers, industry-specific risks).

Brain Ischemia Market Segment Overview

The Global market is further bifurcated into various segments depending on various factors to help the market Size grow as per the predicted CAGR growth by the end of the Forecast period and achieve the expected Brain ischemia market Value.

Based on the condition type, the global market has been segmented as follows:



  • Focal Brain Ischemia

  • Global Brain Ischemia



Based on the treatment, the global market has been segmented as follows:



  • Angioplasty

  • Beta-Blockers

  • Angiotensin-converting enzyme (ACE) Inhibitors

  • Others



Based on the end-user, the market has been segmented as follows:



  • Hospitals & Clinics

  • Research & Academic Institutes

  • Others



Based on the region, the market has been segmented as follows:



  • The Americas

  • Europe

  • Asia-Pacific

  • The Middle East & Africa



Brain Ischemia Market Regional Analysis

The Americas are expected to lead the brain ischemia market because of the increased frequency of brain ischemia and the presence of a well-established healthcare system. Ischemic strokes accounted for 87 percent of all strokes in the United States over

Due to the presence of well-developed healthcare infrastructure, the availability of money for research, and rising healthcare expenditure, Europe is predicted to occupy the second-largest position in the brain ischemia market trends.

Asia-Pacific is predicted to be the fastest-growing regional market because of the existence of expanding nations such as China, India, and South Korea, as well as a huge patient pool suffering from brain ischemia.

The Middle East and Africa's market is predicted to increase modestly because of the existence of developing nations such as Egypt and Saudi Arabia, rising healthcare costs, and the rise of the healthcare industry.

Brain Ischemia Market Competitive Landscape

The competitive landscape for the brain ischemia market breaks out information by the competitor. Financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, company overview, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details included. The major key vendors of the global market are as follows:



  • Taxus Cardium (US)

  • Edwards Lifesciences Corporation (US)

  • Boston Scientific Corporation (US)

  • Merck KGaA (Germany)

  • Medtronic (Ireland), Cook Medical (US)

  • Novartis AG (Switzerland)

  • Boehringer Ingelheim International GmbH (Germany)

  • Abbott (US)

  • Dickinson and Company (US)

  • Johnson & Johnson Services Inc. (US)

  • Bayer AG (Germany), and AstraZeneca (UK)



Recent Developments

The rise in most chronic diseases such as cancer, diabetes, cardiovascular problems, and brain ischemia is due to sedentary lifestyles, bad diets, and lack of exercise but the various players in the market are working on it and taking a step forward.

The significant frequency of brain illnesses among the senior population is due to an increase in research and technical development of the brain ischemia market. The key market players are strategizing about the market growth.

Brain Ischemia Market Report Overview

The research includes detailed information on developing trends, market drivers, development opportunities, and market restraints that may affect the industry's market dynamics. It contains a product, application, and competition analysis, as well as an in-depth examination of the market segments. The Brain Ischemia with strategic analysis, micro and macro market trend and scenarios, pricing analysis, and a holistic assessment of market conditions in the forecast term, this market research study keeps a close eye on major rivals. The study also examines significant players, major collaborations, mergers, and acquisitions, as well as current innovation and corporate policies.

Intended Audience



  • Biotechnology companies



  • Research institutes



  • Medical device companies



  • Pharmaceutical companies



  • Hospitals and clinics



  • Ambulatory surgical centers



  • Academic institutes



  • Government organizations




Report Scope:

Report Attribute/Metric Details
  Market Size   2030 : USD 1,473.7 Million 
  CAGR   7.6% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Information by Condition Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Taxus Cardium (US), Edwards Lifesciences Corporation (US), Boston Scientific Corporation (US), Merck KGaA (Germany), Medtronic (Ireland), Cook Medical (US), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Abbott (US), Becton, Dickinson and Company (US), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK)
  Key Market Opportunities

  • Factors such as the increasing burden of ischemic strokes and growth in the geriatric population which is prone to brain ischemia are expected to drive the market growth.\r\n
  • According to a survey carried out by the World Health Organization (WHO) in 2019
  •   Key Market Drivers   The rising focus of companies for developing drugs for the treatment of brain ischemia is also expected to boost market growth.


    Speak to Analyst Ask for Customization